Combined VTP plus PD-1 inhibitor plus OX40 agonist therapy (VTP+OX40+PD-1) dramatically reduced tumor burden compared with mice treated with either VTP alone or VTP plus a single drug (Supplementary Figures S1 and S2, p < 0.0001). The gene discussed is PDCD1; the disease is neoplasm.